NYMOX PHARMACEUTICAL CORPORATION
NASDAQ : NYMX

NYMOX PHARMACEUTICAL CORPORATION

August 02, 2005 11:36 ET

Second-Hand Smoke Exposure During Pregnancy Puts Fetus at Risk According to New Study; Nymox (NASDAQ:NYMX) TobacAlert™ Product Detects Second-Hand Smoke Exposure

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Aug 2, 2005) -

Nymox Pharmaceutical (NASDAQ:NYMX) makes TobacAlert™, an easy-to-use, cost-effective product that allows for on-site testing for second-hand smoke exposure. TobacAlert™ can be used at home, at school or in the workplace. No instruments are required and results are provided within minutes. Exposure to second-hand smoke during pregnancy can be as harmful to an unborn child as maternal smoking, according to a new study from the University of Pittsburgh (Grant SGG, BMC Pediatr. 2005, 5:20; http://www.biomedcentral.com/bmcpediatr/). Using samples of umbilical cord blood which were tested for genetic marker changes, the study found that exposure to second-hand smoke resulted in abnormal increases in the fetal mutation marker.

"This study provides further evidence of the risks posed by second-hand smoke exposure," according to Brian Doyle, Nymox's Manager of Global Sales and Marketing. "People are often unaware of the nature and extent of second-hand smoke exposure, both to themselves and to their family. TobacAlert™ offers a convenient and easy way to get some objective answers."

TobacAlert™ is available at over 5,400 CVS/pharmacy® stores across the U.S. as well as online at www.cvs.com. More information is available at www.tobacalert.com.

The ability of Nymox's tobacco exposure testing technology to measure second-hand smoke exposure has been successfully put to the test by reporters, as reported recently in the New York Daily News and earlier in the London Sunday Telegraph and Melbourne, Australia's The Sunday Herald Sun.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX
    website: www.nymox.com